Prolyl Carboxypeptidase Maintains Receptor Tyrosine Kinase Signaling and Is a Potential Therapeutic Target in Triple Negative Breast Cancer is a research paper published in Cancers (2022). On theSindex it has a DataRank of 0.339. It has been cited 6 times, with 2 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.292
From this paper's citation signal
Citation Network Contribution
0.0472
From 1 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 2 citers.
National Cancer Institute
Grant: R01CA200232-05
United States Department of Defense
Grant: W81XWH-16-1-0025
NIH HHS
Grant: S10 OD027016
NCI NIH HHS
Grant: R01 CA200232
European Commission
Grant: 200232
A Hungarian Night for Researchers
National Institutes of Health
Grant: 1R01CA200232-01A1
Targeting Prolyl Peptidases in Tamoxifen Resistant Breast Cancer
FWCI
0.39
Citation Percentile
0.5%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals